This AMA episode with Andrew Huberman discusses the risks of Kratom, highlighting its addictive potential and comparing it to other opioids, while also addressing the support it offers for the Huberman Lab Podcast and research funding.
Kratom, derived from the Mitragyna speciosa tree, offers a mild stimulant effect at low dosages but acts as a sedative and an opioid at higher doses, raising concerns about its addictive potential.
The opioid crisis, characterized by the overconsumption and addiction to opioids like morphine and oxycodone, highlights the dangers of opioid addiction, which Kratom, despite its differences, also poses due to its opioid properties.
While some people have used Kratom to wean off more potent opioids, it remains controversial and potentially habit-forming, with the risk of addiction especially at higher dosages.
The response to Kratom varies significantly among individuals, with a subset of the population particularly prone to developing an addiction to opioids, making Kratom a risky choice for these individuals.
Kratom's pharmacology reveals that it acts similarly to other opioids by targeting the mu-opioid receptor, indirectly affecting dopamine and serotonin systems, and suggesting a strong potential for addiction.
Despite being marketed as a supplement, Kratom lacks regulation, and its potency can vary significantly between products, complicating dosage recommendations and increasing the risk of adverse effects, including potential death from respiratory suppression when combined with other substances.
The introduction of the Huberman Lab Podcast premium channel aims to support the podcast and fund research on human health and performance, with a unique dollar-for-dollar match from the Tiny Foundation to double the impact of contributions.
Listeners are encouraged to support research and access premium content, including AMA sessions, by subscribing to the premium channel, contributing to advancements in mental health, physical health, and performance research.
Introduction and Purpose
00:00:00
Andrew Huberman introduces the AMA episode, explaining the goal to support the Huberman Lab Podcast and fund research through the premium subscriber channel.
Kratom's Effects and Risks
00:01:46
Huberman delves into the effects of Kratom, highlighting its dual nature as a stimulant and sedative, and discusses its controversial status due to its opioid properties.
Individual Responses to Kratom
00:09:03
Huberman explains how individual differences affect responses to Kratom, with some people being more prone to addiction.
Pharmacology of Kratom
00:13:45
The neurochemistry and pharmacology of Kratom are discussed, emphasizing its action on the mu-opioid receptor and its indirect effects on dopamine and serotonin systems.
Risks and Regulation of Kratom
00:19:22
The risks associated with Kratom use, including its addictive potential and the lack of regulation over its supplements, are highlighted.
What are the effects of Kratom at low and high dosages?
At low dosages, Kratom has a mild stimulant effect, while at higher dosages, it acts as a sedative and has opioid properties.
How does Kratom's pharmacology relate to its addictive potential?
Kratom acts similarly to other opioids by targeting the mu-opioid receptor and indirectly affecting dopamine and serotonin systems, which suggests a strong potential for addiction.
What advice does Andrew Huberman offer regarding Kratom use?
Huberman advises against using Kratom if you haven't tried it due to its addictive potential and recommends caution about dosage for those who do use it.
Don't let vital information from videos slip away. Begin your journey to efficient learning now.